Autism Spectrum DisorderOxySPECTRUMNCT07555132
Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls
A study testing MDMA in people with Autism Spectrum Disorder, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
This study is to investigate the physiological mechanism of oxytocin system stimulation using 3,4-methylenedioxymethamphetamine (MDMA) as a physiological tool (acute oxytocin releases), not as a medication. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Autism Spectrum Disorder
- What is being tested?
- MDMA
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteSwitzerland
- Study dates
- Jun 2026to Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult patients with a confirmed diagnosis of autism spectrum disorder level 1 according to Diagnostic and Statistical Manual (DSM) V
- Adult healthy controls
- Matched for age, sex, BMI, and oestrogen replacement/menopause/hormonal contraceptives to patients
- No medication, except hormonal contraception
- A score of <32 in the Autism Spectrum Quotient
Who cannot join
- Participation in a trial with investigational drugs within 30 days
- Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months
- Consumption of alcoholic beverages >15 drinks/week
- Tobacco smoking >10 cigarettes/day
- Cardiovascular disease (coronary artery disease, heart failure, left ventricular ejection fraction (LVEF) <40%, stroke in the last 3 months, atrial fibrillation/flutter, Wolff-Parkinson-White (WPW)-Syndrome)
- Uncontrolled arterial hypertension (>140/90 mmHg) or hypotension (<85mmHg)
Show all 13Show fewer
- Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)
- Psychotic disorder in first-degree relatives
- Pregnancy and breastfeeding
- Diagnosed CKD > grade III (GFR < 30ml/min)
- Diagnosed liver cirrhosis or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range
- Confirmed epilepsy diagnosis
- Diagnosed autism spectrum disorder level 2 or 3 (according to DSM V criteria)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site
University Hospital Basel, Endocrinology, Diabetes and Metabolism
Basel, 4031
Mirjam Christ-Crain, Prof. Dr. med., +41 61 265 25 25, mirjam.christ-crain@usb.ch
Mirjam Christ-Crain, Prof. Dr. med.
About this study
This study is to investigate the physiological mechanism of oxytocin system stimulation using 3,4-methylenedioxymethamphetamine (MDMA) as a physiological tool (acute oxytocin releases), not as a medication. This study seeks to test whether the oxytocin response after MDMA administration is different between individuals with autism spectrum disorder and matched healthy controls.
Read the detailed description
Oxytocin is a hypothalamic neuropeptide released both peripherally and centrally that modulates social behavior, emotional processing, and cognition through receptors in regions such as the amygdala, nucleus accumbens, and prefrontal cortex. Clinical, neurobiological, and genetic studies indicate altered oxytocin signaling in autism spectrum disorder (ASD): meta-analyses show lower peripheral oxytocin levels, reduced receptor binding in some brain areas (especially in females), and correlations between higher peripheral oxytocin receptor expression and better social functioning. Over the past two decades, oxytocin has been evaluated as a therapy for ASD, mainly to target social deficits. While exogenous oxytocin can transiently enhance social cognition and connectivity, long-term trials remain inconclusive. As with other hormone deficiencies, single basal oxytocin measurements are unreliable. An emerging alternative is the use of MDMA, which robustly increases circulating oxytocin concentrations in healthy individuals. Measuring oxytocin release after a standardized MDMA challenge could clarify whether ASD patients retain a functional oxytocinergic response, with a blunted release indicating pathway dysfunction.
The OxySPECTRUM study will address this by administering a single dose of MDMA to high- functioning ASD patients and matched neurotypical controls, comparing plasma neurophysin I (equimolar oxytocin surrogate marker) area under curve (AUC) responses.
- Conditions
- Autism Spectrum Disorder
- Being tested
- MDMA, Placebo
- Keywords
- Oxytocin (OT), 3,4-methylenedioxymethamphetamine (MDMA)
- Medical subject headings
- Autism Spectrum Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MDMADiagnostic test
MDMA will be prepared as gelatine capsules containing 25 mg of pharmaceutically pure MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) and mannitol filler. MDMA will be administered in a single dose of 100 mg (4 capsules of 25 mg MDMA)
PlaceboDiagnostic test
Placebos will be prepared as identical gelatine capsules containing only mannitol filler.
| Study group | Role | What they receive |
|---|---|---|
| Patients with ASD | Active comparator | MDMA 100 mg versus placebo, within-subject comparison; randomized to be given MDMA 100 mg or a placebo first in random order. Each participant will present at the study site for two experimental visits. Receives: Diagnostic Test: MDMA; Diagnostic Test: Placebo |
| Healthy controls | Active comparator | MDMA 100 mg versus placebo, within-subject comparison; randomized to be given MDMA 100 mg or a placebo first in random order. Each participant will present at the study site for two experimental visits. Receives: Diagnostic Test: MDMA; Diagnostic Test: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in area under the concentration time curve in plasma neurophysin I
Change in area under the concentration time curve in plasma neurophysin I after a single dose administration of MDMA (100mg) as compared to placebo in the same individuals and compared between ASD patients and healthy controls.
Measured: From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Secondary outcomes (14)
Peak change in plasma oxytocin/neurophysin-I level
Measured: From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Time course of plasma oxytocin/neurophysin-I levels
Measured: From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Time course of plasma MDMA concentration
Measured: From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Time course of pituitary hormone
Measured: From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Change in subjective emotional effects assessed on Subjective effects questionnaire Numeric Analog Scales (NAS)
Subjective emotional effects will be assessed repeatedly using the subjective/emotional effects questionnaire assessed with NAS. NAS will be presented as a range from 0 to 10 marked with "not at all" on the left and "extremely" on the right.
Measured: Throughout the treatment visit (timepoint 0, 30, 60, 90, 120, 150, 180, 240, and 300 minutes)
EmBody/EmFace Task
During the expected peak concentration of MDMA, participants will perform the EmBody/EmFace Task. Each of 42 stimuli showing body or facial expressions of angry, happy, or neutral affect (14 clips per emotion, half in front view and half in half-profile side view from the left). Stimuli last 1.5 seconds at 24 frames per second and are geometrically and optically standardized. Item order is pseudorandom to prevent sequence effects and was determined using the following constraints: the same emotion is shown no more than twice in a row; the same view per emotion is not shown consecutively (i.e., no angry-front, angry-front).
Measured: The test is performed once during each treatment visit and 2-2.5 hours after MDMA administration.
Facial emotion recognition task (FERT)
The FERT is used to assess recognition of basic emotions. The task includes 10 neutral faces and 160 faces that express one of four basic emotions (i.e., happiness, sadness, anger, and fear), with pictures morphed between 0% (neutral) and 100% in 10% steps. Two female and two male pictures are used for each of the four emotions. The outcome measure is accuracy (proportion correct).
Measured: The test is performed once during each treatment visit and 2-2.5 hours after MDMA administration.
Reading the Mind in the Eyes Test (RMET)
The RMET is used to assess theory of mind and emotion recognition from subtle facial cues. The task consists of 36 photographs showing only the eye region of male and female faces. For each photograph, four mental state descriptors (e.g., "anxious," "thoughtful," "playful," "serious") are presented, and participants are asked to choose the word that best matches what the person is feeling or thinking. Stimuli are displayed in random order without time restriction. The primary outcome measure is accuracy (proportion correct), with higher scores reflecting better social-cognitive performance.
Measured: The test is administered once during each treatment visit and 2-2.5 hours after MDMA administration.
Anxiety level with the State-Trait Anxiety Inventory (STAI)
Based on responses to 20 items, with scores ranging from 1 ("almost never") to 4 ("almost always"), a total score is calculated. The total trait score (STAI-T) ranges from 20 to 80, with higher scores indicating more pronounced anxiety and scores.
Measured: The test requires about 5 minutes.
Alexithymia level using the Toronto-Alexithymia-Scale 20 (TAS-20)
The TAS 20 has a three-factor structure: difficulty identifying feelings, difficulty describing feelings and externally oriented thinking. It includes 20 questions with scores ranging from 1 (strongly disagree) to 5 (strongly agree).
Measured: At the screening visit (about 2 minutes)
Depression level using the Beck Depression Inventory II (BDI-II)
The BDI II uses 21 items ranked from 0 (symptom absent) to 3 (severe symptoms) to measure the severity of depression. The minimum score is 0 and maximum score is 63. In non-clinical populations, scores above 20 indicate depression. In those diagnosed with depression, scores of 0-13 indicate minimal depression, 14-19 (mild depression), 20-28 (moderate depression) and 29-63 (severe depression).
Measured: At the screening visit (about 5 minutes)
General physical & mental health using the Patient-Reported Outcomes Measurement Information System (PROMIS)
The PROMIS is a set of person-centred measures that evaluate and monitor physical, mental, and social health. This questionnaire will consist of 29 items. In addition, cognitive functions consisting of 4 items and sociodemographic core data will be asked.
Measured: At the screening visit (about 5 minutes)
Autistic traits level using the Autism-Spectrum Quotient Test (AQ)
This questionnaire is a diagnostic test designed to measure the expression of ASD traits in an individual by his or her subjective self-assessment. The AQ consists of 50 items, with four choices for each item from "definitely agree" to "definitely disagree" and a total score from 0 to 50. A score above the proposed cut-off of 29 highlights significant traits of autism.
Measured: At the screening visit (about 5 minutes)
Autistic traits level using the Comprehensive Autistic Trait Inventory (CATI)
The CATI is a validated 42-item self-report questionnaire measuring autistic traits across six domains: Social Interactions, Communication, Social Camouflage, Repetitive Behaviours, Cognitive Rigidity, and Sensory Sensitivity.
Measured: At the screening visit (about 5 minutes)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2026
- Study startJun 2026 (estimated)
- Primary completionJun 2028 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Autism Spectrum DisorderStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomized, double-blind, placebo-controlled, cross-over (MDMA vs. placebo, within- individual comparison) study in patients versus healthy controls (between-individual comparison)
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mirjam Christ-Crain, Prof. Dr. med., Principal investigator, University Hospital Basel, Endocrinology, Diabetes and Metabolism
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07555132
- Sponsor's protocol ID
- 2025-02452_kt26ChristCrain2
- Other IDs
- 2025
- Acronym
- OxySPECTRUM
- Status last verified
- Apr 2026
- First submitted
- 15 Apr 2026
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls
- ClinicalTrials.gov ID
- NCT07555132
- Acronym / sponsor ID
- OxySPECTRUM / 2025-02452_kt26ChristCrain2
- Conditions
- Autism Spectrum Disorder
- Keywords
- Oxytocin (OT), 3,4-methylenedioxymethamphetamine (MDMA)
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- Jun 2026 (estimated)
- Primary completion
- Jun 2028 (estimated)
- Study completion
- Jun 2028 (estimated)
- First posted
- 29 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to investigate the physiological mechanism of oxytocin system stimulation using 3,4-methylenedioxymethamphetamine (MDMA) as a physiological tool (acute oxytocin releases), not as a medication. This study seeks to test whether the oxytocin response after MDMA administration is different between individuals with autism spectrum disorder and matched healthy controls.
Detailed description
Oxytocin is a hypothalamic neuropeptide released both peripherally and centrally that modulates social behavior, emotional processing, and cognition through receptors in regions such as the amygdala, nucleus accumbens, and prefrontal cortex. Clinical, neurobiological, and genetic studies indicate altered oxytocin signaling in autism spectrum disorder (ASD): meta-analyses show lower peripheral oxytocin levels, reduced receptor binding in some brain areas (especially in females), and correlations between higher peripheral oxytocin receptor expression and better social functioning. Over the past two decades, oxytocin has been evaluated as a therapy for ASD, mainly to target social deficits. While exogenous oxytocin can transiently enhance social cognition and connectivity, long-term trials remain inconclusive. As with other hormone deficiencies, single basal oxytocin measurements are unreliable. An emerging alternative is the use of MDMA, which robustly increases circulating oxytocin concentrations in healthy individuals. Measuring oxytocin release after a standardized MDMA challenge could clarify whether ASD patients retain a functional oxytocinergic response, with a blunted release indicating pathway dysfunction.
The OxySPECTRUM study will address this by administering a single dose of MDMA to high- functioning ASD patients and matched neurotypical controls, comparing plasma neurophysin I (equimolar oxytocin surrogate marker) area under curve (AUC) responses.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Randomized, double-blind, placebo-controlled, cross-over (MDMA vs. placebo, within- individual comparison) study in patients versus healthy controls (between-individual comparison)
| Arm | Type | Receives |
|---|---|---|
| Patients with ASD | Active comparator | Diagnostic Test: MDMA, Diagnostic Test: PlaceboMDMA 100 mg versus placebo, within-subject comparison; randomized to be given MDMA 100 mg or a placebo first in random order. Each participant will present at the study site for two experimental visits. |
| Healthy controls | Active comparator | Diagnostic Test: MDMA, Diagnostic Test: PlaceboMDMA 100 mg versus placebo, within-subject comparison; randomized to be given MDMA 100 mg or a placebo first in random order. Each participant will present at the study site for two experimental visits. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adult patients with a confirmed diagnosis of autism spectrum disorder level 1 according to Diagnostic and Statistical Manual (DSM) V
- Adult healthy controls
- Matched for age, sex, BMI, and oestrogen replacement/menopause/hormonal contraceptives to patients
- No medication, except hormonal contraception
- A score of <32 in the Autism Spectrum Quotient
Key exclusion criteria (13 listed)
- Participation in a trial with investigational drugs within 30 days
- Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months
- Consumption of alcoholic beverages >15 drinks/week
- Tobacco smoking >10 cigarettes/day
- Cardiovascular disease (coronary artery disease, heart failure, left ventricular ejection fraction (LVEF) <40%, stroke in the last 3 months, atrial fibrillation/flutter, Wolff-Parkinson-White (WPW)-Syndrome)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MDMAMDMA will be prepared as gelatine capsules containing 25 mg of pharmaceutically pure MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) and mannitol filler. MDMA will be administered in a single dose of 100 mg (4 capsules of 25 mg MDMA) | Diagnostic test | Healthy controls, Patients with ASD |
| PlaceboPlacebos will be prepared as identical gelatine capsules containing only mannitol filler. | Diagnostic test | Healthy controls, Patients with ASD |
Primary outcome
Change in area under the concentration time curve in plasma neurophysin I
Time frame: From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Change in area under the concentration time curve in plasma neurophysin I after a single dose administration of MDMA (100mg) as compared to placebo in the same individuals and compared between ASD patients and healthy controls.
14 secondary outcomes
Peak change in plasma oxytocin/neurophysin-I level
Time frame: From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Time course of plasma oxytocin/neurophysin-I levels
Time frame: From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Time course of plasma MDMA concentration
Time frame: From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Time course of pituitary hormone
Time frame: From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Change in subjective emotional effects assessed on Subjective effects questionnaire Numeric Analog Scales (NAS)
Time frame: Throughout the treatment visit (timepoint 0, 30, 60, 90, 120, 150, 180, 240, and 300 minutes)
EmBody/EmFace Task
Time frame: The test is performed once during each treatment visit and 2-2.5 hours after MDMA administration.
Facial emotion recognition task (FERT)
Time frame: The test is performed once during each treatment visit and 2-2.5 hours after MDMA administration.
Reading the Mind in the Eyes Test (RMET)
Time frame: The test is administered once during each treatment visit and 2-2.5 hours after MDMA administration.
Anxiety level with the State-Trait Anxiety Inventory (STAI)
Time frame: The test requires about 5 minutes.
Alexithymia level using the Toronto-Alexithymia-Scale 20 (TAS-20)
Time frame: At the screening visit (about 2 minutes)
Depression level using the Beck Depression Inventory II (BDI-II)
Time frame: At the screening visit (about 5 minutes)
General physical & mental health using the Patient-Reported Outcomes Measurement Information System (PROMIS)
Time frame: At the screening visit (about 5 minutes)
Autistic traits level using the Autism-Spectrum Quotient Test (AQ)
Time frame: At the screening visit (about 5 minutes)
Autistic traits level using the Comprehensive Autistic Trait Inventory (CATI)
Time frame: At the screening visit (about 5 minutes)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
Related trials for Autism Spectrum Disorder
RecruitingPhase 1
Cannabidiol (CBD) in Adults With ASD
Autism Spectrum Disorder
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Sensory-integration Therapy Verses Augumented Reality-based Training in ASD
Autism Spectrum Disorder
Recruiting
Cumulative and Booster Effects of Multisession Prefrontal tDCS in ASD Adolescents
Transcranial Direct Current Stimulation, Autistic Spectrum Disorder
Not yet recruiting
"Family Resilience And Mind-body Enhancement" (FRAME): A Randomised Controlled Trial
Autism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mirjam Christ-Crain, Prof. Dr. med. principal investigator
University Hospital Basel, Endocrinology, Diabetes and Metabolism
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MDMA in people with Autism Spectrum Disorder, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mirjam Christ-Crain, Prof. Dr. med. (+41 61 265 25 25, mirjam.christ-crain@usb.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in area under the concentration time curve in plasma neurophysin I (time frame: From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.